MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

MacroGenics, Inc.NASDAQ: MGNX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $9.71M fell 9.4% year over year, ahead of the -27.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.

Context

  • Selling, general & admin amounted to 26.2% of revenue in FY2025, down 21.7 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $60.68M (+54.9%) for the fiscal year ending Dec 2026, a step up from the -44.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.71M+5.1% QoQ
Last fiscal yearDec 2025
$39.16M-44.9% YoY
LTMMar 2026
$38.15M-27.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.4%+266.1%+275.5 pp
1 year-44.9%+54.9%+99.8 pp
3-year CAGR-12.7%+14.4%+27.2 pp
5-year CAGR+11.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
39.16M USD
Year-over-year change
-44.9%
4-year CAGR
-11.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.9% is the 8th highest of 11, against a peer median of -6.6%.
  • Selling, general & admin amounts to 24.3% of revenue for MGNX, versus a peer median of 18839.1%.
MGNX Competitors
Selling, General & Admin for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$6.7B USD+73001.9%+33.2%84342.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$34.97M USD-57.3%-11.6%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.75M USD-6.4%-9.4%347.5%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$23.29M USD-40.2%-9.5%—
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$8.48M USD+21.4%-17.7%—
CNTXContext Therapeutics Inc.LTM Mar 2026$8.11M USD+9.0%+0.2%—
CLNNClene Inc.LTM Mar 2026$7.9M USD-34.1%-17.0%5897.0%
Peer median (excluding MGNX) —-6.6%-6.9%18839.1%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.